{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:32:41Z","timestamp":1793809961013,"version":"4.6.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"am","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA057289"],"award-info":[{"award-number":["R01DA057289"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.disamonth.2024.101851","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T15:01:34Z","timestamp":1736866894000},"page":"101851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug"],"prefix":"10.1016","volume":"71","author":[{"given":"Andrew M.","family":"Farrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle H.","family":"Nordstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Shelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayane","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn N.","family":"Kunstman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Palamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0001","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hup.2318","article-title":"Human psychobiology of MDMA or \u2018Ecstasy\u2019: an overview of 25 years of empirical research","volume":"28","author":"Parrott","year":"2013","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0002","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","article-title":"Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens","volume":"18","author":"Nichols","year":"1986","journal-title":"J Psychoactive Drugs"},{"issue":"13","key":"10.1016\/j.disamonth.2024.101851_bib0003","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1080\/10826084.2020.1799231","article-title":"Diffusion of ecstasy in the electronic dance music scene","volume":"55","author":"Palamar","year":"2020","journal-title":"Subst Use Misuse"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101851_bib0004","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.disamonth.2024.101851_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-024-01622-3","article-title":"MDMA therapy for PTSD rejected by FDA panel","author":"Reardon","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.disamonth.2024.101851_bib0006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/SAR.S37258","article-title":"3,4-methylenedioxymethamphetamine (MDMA): current perspectives","volume":"4","author":"Meyer","year":"2013","journal-title":"Subst Abuse Rehabil"},{"key":"10.1016\/j.disamonth.2024.101851_bib0007","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2016.02.001","article-title":"Detection of \u201cbath salts\u201d and other novel psychoactive substances in hair samples of ecstasy\/MDMA\/\u201cMolly\u201d users","volume":"161","author":"Palamar","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.disamonth.2024.101851_bib0008","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1360-0443.2006.01511.x","article-title":"The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents","volume":"101","author":"Freudenmann","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.disamonth.2024.101851_bib0009","unstructured":"Shulgin A., Shulgin A. Pihkal: a Chemical Love Story.; 1990."},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/02791072.2015.1128580","article-title":"The history of MDMA as an underground drug in the United States, 1960-1979","volume":"48","author":"Passie","year":"2016","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0011","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2307\/1142315","article-title":"Problems in identification of methylenediony and methoxy amphetamines","volume":"63","author":"Sreenivasan","year":"1972","journal-title":"J Crim Law Criminol Police Sci"},{"key":"10.1016\/j.disamonth.2024.101851_sbref0012","series-title":"The Psychopharmacology of Hallucinogens","article-title":"Characterization of Three New Psychotomimetics","author":"Shulgin","year":"1978"},{"key":"10.1016\/j.disamonth.2024.101851_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/2050324518767442","article-title":"The early use of MDMA (\u2018Ecstasy\u2019) in psychotherapy (1977\u20131985)","volume":"4","author":"Passie","year":"2018","journal-title":"Drug Sci Policy Law"},{"key":"10.1016\/j.disamonth.2024.101851_bib0014","series-title":"Pursuit of Ecstasy: The MDMA Experience","author":"Beck","year":"1994"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02791072.2001.10400568","article-title":"An exploration of the history and controversies surrounding MDMA and MDA","volume":"33","author":"Pentney","year":"2001","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.disamonth.2024.101851_bib0016","series-title":"The History of MDMA","article-title":"The Scheduling","author":"Passie","year":"2023"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0017","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13181-013-0295-x","article-title":"2C or Not 2C: phenethylamine designer drug review","volume":"9","author":"Dean","year":"2013","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.disamonth.2024.101851_bib0018","unstructured":"Government of Canada PW and GSC. Canada Gazette, Part 2, Volume 156, Number 1: Regulations Amending Certain Regulations Relating to Restricted Drugs (Special Access Program). January 5, 2022. Accessed November 26, 2024. https:\/\/www.gazette.gc.ca\/rp-pr\/p2\/2022\/2022-01-05\/html\/sor-dors271-eng.html."},{"key":"10.1016\/j.disamonth.2024.101851_bib0019","unstructured":"Therapeutic Goods Administration. Notice of final decisions to amend (or not amend) the current Poisons Standard in relation to psilocybine and MDMA. Canberra ACT Aust Dep Health Commonw Aust. Published online 2023."},{"issue":"8","key":"10.1016\/j.disamonth.2024.101851_bib0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4140\/TCP.n.2024.311","article-title":"Therapy for PTSD: inching Closer to\u2013or Farther From\u2013Approval?","volume":"39","author":"Davitian","year":"2024","journal-title":"Sr Care Pharm"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelics Drug Legislative Reform ant legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.disamonth.2024.101851_bib0022","unstructured":"Lykos Therapeutics, ed. Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD. Published online August 9, 2024. https:\/\/news.lykospbc.com\/2024-08-09-Lykos-Therapeutics-Announces-Complete-Response-Letter-for-Midomafetamine-Capsules-for-PTSD."},{"key":"10.1016\/j.disamonth.2024.101851_bib0023","article-title":"FDA rejects ecstasy as a therapy: what's next for psychedelics?","volume":"13","author":"Reardon","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.disamonth.2024.101851_bib0024","unstructured":"Center for Behavioral Health and Quality. Results from the 2023 National Survey on Drug Use and Health: Detailed tables. Published online. 2024. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-detailed-tables."},{"key":"10.1016\/j.disamonth.2024.101851_bib0025","article-title":"Monitoring the Future national survey results on drug use, 1975\u20132023: overview and detailed results for secondary school students","author":"Miech","year":"2024","journal-title":"Ann Arbor MI Inst Soc Res Univ Mich"},{"key":"10.1016\/j.disamonth.2024.101851_bib0026","article-title":"European Monitoring Centre for Drugs and Drug Addiction","year":"2024","journal-title":"European Drug Report 2024: Trends and Developments"},{"key":"10.1016\/j.disamonth.2024.101851_bib0027","article-title":"National Drug Strategy Household Survey 2022\u20132023: ecstasy in the NDSHS","year":"2024","journal-title":"Australian Institute of Health and Welfare"},{"issue":"13","key":"10.1016\/j.disamonth.2024.101851_bib0028","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3109\/10826084.2014.926933","article-title":"An Examination of Sociodemographic Correlates of Ecstasy Use Among High School Seniors in the United States","volume":"49","author":"Palamar","year":"2014","journal-title":"Subst Use Misuse"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0029","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/02698811221127304","article-title":"Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA\/ecstasy and psilocybin) and major depressive episodes","volume":"37","author":"Jones","year":"2023","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0030","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11606-019-05176-3","article-title":"Summer as a risk factor for drug initiation","volume":"35","author":"Palamar","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101851_bib0031","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/ADM.0000000000001188","article-title":"Prevalence and correlates of past year ecstasy\/MDMA use in the United States","volume":"17","author":"Yang","year":"2023","journal-title":"J Addict Med"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0032","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/10826084.2016.1219373","article-title":"Self-reported ecstasy\/MDMA\/\u201cMolly\u201d use in a sample of nightclub and dance festival attendees in New York city","volume":"52","author":"Palamar","year":"2017","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.disamonth.2024.101851_bib0033","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fpsyt.2019.00650","article-title":"Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline","volume":"10","author":"Feduccia","year":"2019","journal-title":"Front Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.disamonth.2024.101851_bib0034","first-page":"88","article-title":"Substance use in severe mental illness: self-medication and vulnerability factors","volume":"165","author":"Bizzarri","year":"2007","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1556\/2054.2018.006","article-title":"Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics","volume":"2","author":"Mason","year":"2018","journal-title":"J Psychedelic Stud"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101851_bib0036","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.addbeh.2012.05.022","article-title":"Antidepressant-like effects of ecstasy in subjects with a predisposition to depression","volume":"37","author":"Majumder","year":"2012","journal-title":"Addict Behav"},{"key":"10.1016\/j.disamonth.2024.101851_bib0037","unstructured":"United Nations convention against illicit traffic in narcotic drugs and psychotropic substances, 1988."},{"key":"10.1016\/j.disamonth.2024.101851_bib0038","series-title":"Report On the Sixty-Second Session","year":"2019"},{"key":"10.1016\/j.disamonth.2024.101851_bib0039","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/emj.2010.092270","article-title":"Variability in the 3,4-methylenedioxymethamphetamine content of \u201cecstasy\u201d tablets in the UK","volume":"28","author":"Wood","year":"2011","journal-title":"Emerg Med J EMJ"},{"key":"10.1016\/j.disamonth.2024.101851_bib0040","series-title":"European Drug Report 2016: Trends and Developments","year":"2016"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101851_bib0041","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/ajhp\/59.11.1067","article-title":"Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate","volume":"59","author":"Smith","year":"2002","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm"},{"issue":"17","key":"10.1016\/j.disamonth.2024.101851_bib0042","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1001\/jama.284.17.2190","article-title":"Chemical analysis of ecstasy pills","volume":"284","author":"Baggott","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0043","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/emj.16.3.194","article-title":"Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department","volume":"16","author":"Sherlock","year":"1999","journal-title":"J Accid Emerg Med"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0044","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00213-018-5066-6","article-title":"Synthetic cathinone adulteration of illegal drugs","volume":"236","author":"Oliver","year":"2019","journal-title":"Psychopharmacol (Berl)"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.drugalcdep.2005.11.016","article-title":"Pharmacological content of tablets sold as \u201cecstasy\u201d: results from an online testing service","volume":"83","author":"EE","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101851_bib0046","first-page":"40","article-title":"Persistent psychosis and medical complications after a single ingestion of MDMA \u201cEcstasy\u201d: a case report and review of the literature","volume":"6","author":"Potash","year":"2009","journal-title":"Psychiatry Edgmont Pa Townsh"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101851_bib0047","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","article-title":"Mechanisms of neurotransmitter release by amphetamines: a review","volume":"75","author":"Sulzer","year":"2005","journal-title":"Prog Neurobiol"},{"issue":"14","key":"10.1016\/j.disamonth.2024.101851_bib0048","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/0006-2952(87)90594-6","article-title":"Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain","volume":"36","author":"Steele","year":"1987","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0049","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","article-title":"Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites","volume":"149","author":"Battaglia","year":"1988","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","article-title":"MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment","volume":"189","author":"Verrico","year":"2007","journal-title":"Psychopharmacol (Berl)"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0051","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1471-4159.2009.06474.x","article-title":"The reverse operation of Na+\/Cl\u2212-coupled neurotransmitter transporters\u2013why amphetamines take two to tango","volume":"112","author":"Sitte","year":"2010","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0052","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1124\/jpet.106.103622","article-title":"Interaction of amphetamines and related compounds at the vesicular monoamine transporter","volume":"319","author":"Partilla","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101851_bib0053","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1046\/j.1460-9568.2003.02884.x","article-title":"Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT[sub 1B] receptors located on CA1 pyramidal neurons","volume":"18","author":"Mlinar","year":"2003","journal-title":"Eur J Neurosci"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0054","first-page":"275","article-title":"Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raph\u00e9 nucleus slices","volume":"36","author":"Iravani","year":"2000","journal-title":"Synap N Y N"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/026988110001400313","article-title":"The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy\u2019) in healthy volunteers","volume":"14","author":"Liechti","year":"2000","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0056","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.107.129056","article-title":"Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics","volume":"323","author":"Farr\u00e9","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101851_bib0057","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1046\/j.1471-4159.1999.0722516.x","article-title":"Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum","volume":"72","author":"Shankaran","year":"1999","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0058","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.105.084426","article-title":"Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters","volume":"314","author":"Pifl","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0059","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/npp.1994.26","article-title":"MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac)","volume":"10","author":"Leonardi","year":"1994","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.disamonth.2024.101851_bib0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.toxlet.2015.12.001","article-title":"Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine","volume":"243","author":"Steuer","year":"2016","journal-title":"Toxicol Lett"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101851_bib0061","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/sj.bjp.0702875","article-title":"Investigation of the prejunctional \u03b12-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens","volume":"128","author":"Lavelle","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101851_bib0062","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/10408444.2012.725029","article-title":"Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug\u2013drug interactions","volume":"42","author":"Rietjens","year":"2012","journal-title":"Crit Rev Toxicol"},{"issue":"23","key":"10.1016\/j.disamonth.2024.101851_bib0063","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1016\/0006-2952(87)90566-1","article-title":"Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine","volume":"36","author":"Schmidt","year":"1987","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0064","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuroscience.2008.03.086","article-title":"3,4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleus","volume":"155","author":"Bonkale","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.disamonth.2024.101851_bib0065","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuropharm.2017.10.003","article-title":"Separating the agony from ecstasy: R(\u2212)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice","volume":"128","author":"Curry","year":"2018","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0066","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2125.2000.00121.x","article-title":"Non-linear pharmacokinetics of MDMA ('ecstasy\u2019) in humans","volume":"49","author":"de la Torre","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0067","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","article-title":"Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition","volume":"26","author":"de la Torre","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0068","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00003088-200443030-00002","article-title":"Clinical pharmacokinetics of amfetamine and related substances","volume":"43","author":"de la Torre","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101851_bib0069","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0006-2952(00)00284-7","article-title":"Identification of the human cytochromes P450 involved in the oxidative metabolism of \u201cEcstasy\u201d-related designer drugs","volume":"59","author":"Kreth","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101851_bib0070","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1124\/dmd.108.021543","article-title":"The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers","volume":"36","author":"Meyer","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0071","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/03602532.2019.1697283","article-title":"Adverse pharmacokinetic interactions between illicit substances and clinical drugs","volume":"52","author":"Abbott","year":"2020","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0072","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12035-009-8064-1","article-title":"Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview","volume":"39","author":"Capela","year":"2009","journal-title":"Mol Neurobiol"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101851_bib0073","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0074","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","article-title":"Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects","volume":"27","author":"Vizeli","year":"2017","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101851_bib0075","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1124\/dmd.104.001180","article-title":"Mechanism-based inactivation of Cyp2d6 by methylenedioxymethamphetamine","volume":"32","author":"Heydari","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101851_bib0076","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/JCP.0b013e318184ff6e","article-title":"The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans","volume":"28","author":"O'Math\u00fana","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0077","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1360-0443.2003.00292.x","article-title":"Death following ingestion of MDMA (ecstasy) and moclobemide","volume":"98","author":"Vuori","year":"2003","journal-title":"Addict Abingdon Engl"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0078","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/anatox\/35.4.219","article-title":"Deaths involving MDMA and the concomitant use of pharmaceutical drugs","volume":"35","author":"Pilgrim","year":"2011","journal-title":"J Anal Toxicol"},{"issue":"1\u20133","key":"10.1016\/j.disamonth.2024.101851_bib0079","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.forsciint.2011.04.008","article-title":"Serotonin toxicity involving MDMA (ecstasy) and moclobemide","volume":"215","author":"Pilgrim","year":"2012","journal-title":"Forens Sci Int"},{"issue":"9142","key":"10.1016\/j.disamonth.2024.101851_bib0080","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(05)79824-X","article-title":"Fatal interaction between ritonavir and MDMA","volume":"352","author":"Henry","year":"1998","journal-title":"Lancet Lond Engl"},{"issue":"18","key":"10.1016\/j.disamonth.2024.101851_bib0081","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/archinte.159.18.2221","article-title":"Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate","volume":"159","author":"Harrington","year":"1999","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0082","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/jpet.114.222356","article-title":"Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects","volume":"353","author":"Schmid","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"10.1016\/j.disamonth.2024.101851_bib0083","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/15563658708992620","article-title":"A case of MAO inhibitor\/MDMA interaction: agony after ecstasy","volume":"25","author":"Smilkstein","year":"1987","journal-title":"J Toxicol Clin Toxicol"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0084","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1017\/S1461145713001132","article-title":"Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination","volume":"17","author":"Hysek","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","article-title":"The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans","volume":"90","author":"Hysek","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0086","first-page":"85","article-title":"Stimulant and designer drug use: primary care management","volume":"98","author":"Klega","year":"2018","journal-title":"Am Fam Physician"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101851_bib0087","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/02791072.2002.10399951","article-title":"Acute psychological and neurophysiological effects of MDMA in humans","volume":"34","author":"Vollenweider","year":"2002","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.disamonth.2024.101851_bib0088","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/1471-244X-12-221","article-title":"Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable?","volume":"12","author":"Bramness","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.disamonth.2024.101851_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.694863","article-title":"Substance-induced psychoses: an updated literature review","volume":"12","author":"Fiorentini","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.disamonth.2024.101851_bib0090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12888-016-1002-7","article-title":"Psychosis associated with acute recreational drug toxicity: a European case series","volume":"16","author":"Vallersnes","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.disamonth.2024.101851_bib0091","first-page":"947","volume":"xliv","year":"2013"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101851_bib0092","first-page":"2333","article-title":"The health effect of psychostimulants: a literature review","volume":"3","author":"Favrod-Coune","year":"2010","journal-title":"Pharm Basel Switz"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101851_bib0093","first-page":"917","article-title":"The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs","volume":"165","author":"Kalant","year":"2001","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0094","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00213-004-1791-0","article-title":"Chronic MDMA (ecstasy) use, cognition and mood","volume":"173","author":"McCardle","year":"2004","journal-title":"Psychopharmacol (Berl)"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101851_bib0095","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/bja\/ael078","article-title":"Acute toxic effects of \u2018Ecstasy\u2019 (MDMA) and related compounds: overview of pathophysiology and clinical management","volume":"96","author":"Hall","year":"2006","journal-title":"BJA Br J Anaesth"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0096","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0278-5846(97)00045-6","article-title":"Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: \u201cEcstasy\u201d)","volume":"21","author":"Cohen","year":"1997","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0097","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/157015911795017146","article-title":"The nature of 3, 4-methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: evidence for and against the neurodegeneration hypothesis","volume":"9","author":"Biezonski","year":"2011","journal-title":"Curr Neuropharmacol"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101851_bib0098","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tips.2004.08.001","article-title":"Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans","volume":"25","author":"De","year":"2004","journal-title":"Trend Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101851_bib0099","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1476-5381.2011.01819.x","article-title":"Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans","volume":"166","author":"Green","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.disamonth.2024.101851_bib0100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neubiorev.2016.02.003","article-title":"Meta-analysis of molecular imaging of serotonin transporters in ecstasy\/polydrug users","volume":"63","author":"Roberts","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0101","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1192\/bjp.bp.108.050344","article-title":"Brain serotonin transporter binding in former users of MDMA (\u2018ecstasy\u2019)","volume":"194","author":"Selvaraj","year":"2009","journal-title":"Br J Psychiatry"},{"issue":"8","key":"10.1016\/j.disamonth.2024.101851_bib0102","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1017\/S0033291716000258","article-title":"Meta-analysis of executive functioning in ecstasy\/polydrug users","volume":"46","author":"Roberts","year":"2016","journal-title":"Psychol Med"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101851_bib0103","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00213-013-3325-0","article-title":"Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users","volume":"231","author":"Wetherell","year":"2013","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.disamonth.2024.101851_bib0104","article-title":"Neurotoxicity of MDMA: main effects and mechanisms","volume":"347","author":"Costa","year":"2021","journal-title":"Exp Neurol"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101851_bib0105","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1360-0443.2009.02649.x","article-title":"Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study","volume":"104","author":"Cottler","year":"2009","journal-title":"Addict Abingdon Engl"},{"key":"10.1016\/j.disamonth.2024.101851_bib0106","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/bs.irn.2015.02.005","article-title":"\u201cAddicted to Euphoria\u201d: the history, clinical presentation, and management of party drug misuse","volume":"120","author":"Bearn","year":"2015","journal-title":"Int Rev Neurobiol"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0107","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0091-3057(01)00711-0","article-title":"Recreational Ecstasy\/MDMA, the serotonin syndrome, and serotonergic neurotoxicity","volume":"71","author":"Parrott","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00213-001-0995-9","article-title":"Sub-acute effects of MDMA (\u00b13,4-methylenedioxymethamphetamine, \u201cecstasy\u201d) on mood: evidence of gender differences","volume":"161","author":"Verheyden","year":"2002","journal-title":"Psychopharmacol (Berl)"},{"issue":"Journal Article","key":"10.1016\/j.disamonth.2024.101851_bib0109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugalcdep.2014.02.697","article-title":"The effect of the ecstasy \u201ccome-down\u201d on the diagnosis of ecstasy dependence","volume":"139","author":"McKetin","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.09.009","article-title":"Is ecstasy a drug of dependence?","volume":"107","author":"Degenhardt","year":"2010","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0111","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0091-3057(90)90301-W","article-title":"Tolerance and cross-tolerance to 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine","volume":"35","author":"Zacny","year":"1990","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0112","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.neuroscience.2008.01.007","article-title":"Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges","volume":"152","author":"Baumann","year":"2008","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0113","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0269881105048900","article-title":"Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy","volume":"19","author":"Parrott","year":"2005","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0114","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00213-012-2894-7","article-title":"Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart","volume":"225","author":"Peir\u00f3","year":"2013","journal-title":"Psychopharmacol (Berl)"},{"issue":"Journal Article","key":"10.1016\/j.disamonth.2024.101851_bib0115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnins.2020.00078","article-title":"NBOMes-highly potent and toxic alternatives of LSD","volume":"14","author":"Zawilska","year":"2020","journal-title":"Front Neurosci"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101851_bib0116","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/phar.1424","article-title":"Not for human consumption\u201d: a review of emerging designer drugs","volume":"34","author":"Musselman","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0117","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.disamonth.2014.01.001","article-title":"Emerging drugs of abuse","volume":"60","author":"Nelson","year":"2014","journal-title":"Dis\u2013Mon DM"},{"issue":"Journal Article","key":"10.1016\/j.disamonth.2024.101851_bib0118","first-page":"w14043","article-title":"Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling","volume":"145","author":"Liechti","year":"2015","journal-title":"Swiss Med Wkly"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101851_bib0119","doi-asserted-by":"crossref","first-page":"616","DOI":"10.12968\/bjon.2018.27.11.616","article-title":"MDMA toxicity: management of acute and life-threatening presentations","volume":"27","author":"Davies","year":"2018","journal-title":"Br J Nurs Mark Allen Publ"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccc.2021.03.002","article-title":"Drugs of Abuse: sympathomimetics","volume":"37","author":"Brown","year":"2021","journal-title":"Crit Care Clin"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0121","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0196-0644(94)70165-2","article-title":"Hyperthermia in psychostimulant overdose","volume":"24","author":"Callaway","year":"1994","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.disamonth.2024.101851_bib0122","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00740","article-title":"Antipsychotics for amphetamine psychosis. a systematic review","volume":"10","author":"Fluyau","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.disamonth.2024.101851_bib0123","series-title":"Amphetamine-Related Psychiatric Disorders","author":"Mullen","year":"2024"},{"key":"10.1016\/j.disamonth.2024.101851_bib0124","doi-asserted-by":"crossref","unstructured":"Principles of Drug Addiction Treatment: A Research-Based Guide: Third Edition: (686332012-001). Published online 2014. doi:10.1037\/e686332012-001.","DOI":"10.1037\/e686332012-001"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02791072.2009.10400672","article-title":"What's in a label? Ecstasy sellers\u2019 perceptions of pill brands","volume":"41","author":"Duterte","year":"2009","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08897077.2016.1267070","article-title":"There's something about molly: the under-researched yet popular powder form of ecstasy in the United States","volume":"38","author":"Palamar","year":"2017","journal-title":"Subst Abuse"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0127","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/02791072.2017.1369200","article-title":"What's in a name? Correlates of ecstasy users knowing or agreeing that molly is ecstasy\/MDMA","volume":"50","author":"Palamar","year":"2018","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.disamonth.2024.101851_bib0128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12954-022-00598-5","article-title":"A qualitative investigation exploring why dance festivals are risky environments for drug use and potential adverse outcomes","volume":"19","author":"Palamar","year":"2022","journal-title":"Harm Reduct J"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dar.12882","article-title":"Prevalence of reagent test-kit use and perceptions of purity among ecstasy users in an electronic dance music scene in New York City","volume":"38","author":"Palamar","year":"2019","journal-title":"Drug Alcohol Rev"},{"issue":"8","key":"10.1016\/j.disamonth.2024.101851_bib0130","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/0269881117715596","article-title":"Who is \u201cMolly\u201d? MDMA adulterants by product name and the impact of harm-reduction services at raves","volume":"31","author":"Saleemi","year":"2017","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14659891.2019.1664660","article-title":"The influence of viewing a headline about ecstasy\/Molly adulteration on future intentions to use","volume":"25","author":"Palamar","year":"2020","journal-title":"J Subst Use"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101851_bib0132","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/add.15734","article-title":"Drug checking services for people who use drugs: a systematic review","volume":"117","author":"Maghsoudi","year":"2022","journal-title":"Addict Abingdon Engl"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101851_bib0133","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/02791072.1986.10472371","article-title":"MDMA on the street: analysis anonymous","volume":"18","author":"Renfroe","year":"1986","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.disamonth.2024.101851_bib0134","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.596895","article-title":"Drug checking as strategy for harm reduction in recreational contests: evaluation of two different drug analysis methodologies","volume":"12","author":"Fregonese","year":"2021","journal-title":"Front Psychiatry"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12954-017-0179-5","article-title":"An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services","volume":"14","author":"Harper","year":"2017","journal-title":"Harm Reduct J"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0136","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12954-023-00764-3","article-title":"Point-of-care community drug checking technologies: an insider look at the scientific principles and practical considerations","volume":"20","author":"Gozdzialski","year":"2023","journal-title":"Harm Reduct J"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101851_bib0137","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12954-021-00478-4","article-title":"High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips","volume":"18","author":"Lockwood","year":"2021","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.disamonth.2024.101851_bib0138","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-023-00921-8","article-title":"Testing the test strips: laboratory performance of fentanyl test strips","volume":"21","author":"Halifax","year":"2024","journal-title":"Harm Reduct J"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502924001779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502924001779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:51:25Z","timestamp":1742734285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502924001779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":138,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0011502924001779"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2024.101851","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2024.101851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101851"}}